Each individual with obtainable data treated with teprotumumab had some extent of reduced amount of proptosis (Fig

Each individual with obtainable data treated with teprotumumab had some extent of reduced amount of proptosis (Fig.?5a) and CAS (Fig.?5b) in week 24. Open in another window Fig. sufferers (p?Eriodictyol Within the lack of effective pharmacotherapies, the only real option still left for Mouse monoclonal to IL-2 sufferers is eventual medical procedures after the inflammatory procedure subsides. Teprotumumab, a individual monoclonal IGF-1R antagonist completely, is in development currently.

---